loading...| Preferred Name |
Stanozolol |
|
| Synonyms |
|
|
| Definitions |
An orally active synthetic anabolic steroid and a 17alpha-alkylated derivative of dihydrotestosterone that is formed by the condensation of the 3-keto-aldehyde moiety of oxymetholone with hydrazine, with androgenic activity. Although stanozolol has low affinity for binding the androgen receptor (AR), it strongly activates AR-mediated signaling, which stimulates both protein synthesis and erythropoietin production. This agent may stimulate fat loss while retaining lean body mass, and may induce hemoglobin production and red blood cell formation; therefore, stanozolol may be used to treat wasting diseases or anemia. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C842 |
|
| CAS_Registry |
10418-03-8 |
|
| Chemical_Formula |
C21H32N2O |
|
| code |
C842 |
|
| Contributing_Source |
FDA |
|
| definition |
An orally active synthetic anabolic steroid and a 17alpha-alkylated derivative of dihydrotestosterone that is formed by the condensation of the 3-keto-aldehyde moiety of oxymetholone with hydrazine, with androgenic activity. Although stanozolol has low affinity for binding the androgen receptor (AR), it strongly activates AR-mediated signaling, which stimulates both protein synthesis and erythropoietin production. This agent may stimulate fat loss while retaining lean body mass, and may induce hemoglobin production and red blood cell formation; therefore, stanozolol may be used to treat wasting diseases or anemia. |
|
| FDA_UNII_Code |
4R1VB9P8V3 |
|
| in_subset | ||
| label |
Stanozolol |
|
| Legacy Concept Name |
Stanozolol |
|
| NCI_Drug_Dictionary_ID |
39267 |
|
| NSC Number |
233046 43193 |
|
| PDQ_Closed_Trial_Search_ID |
39267 |
|
| PDQ_Open_Trial_Search_ID |
39267 |
|
| Preferred_Name |
Stanozolol |
|
| prefixIRI |
NCIT:C842 |
|
| prefLabel |
Stanozolol |
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance |
|
| UMLS_CUI |
C0038149 |
|
| subClassOf |